Figure 3From: Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis Change in lipid profiles, AI, mFRS, and IR after therapy with or without biologics. (A1) The changes in serum levels of lipid profile after 6 months of therapy in adalimumab-treated patients. (A2) The changes in AI, mFRS, and IR after 6 months of therapy in adalimumab-treated patients. (B1) The changes in serum levels of lipid profile after 6 months of therapy in etanercept-treated patients. (B2) The changes in AI, mFRS, and IR after 6 months of therapy in etanercept-treated patients. (C1) The changes in serum levels of lipid profile after 6 months of therapy in tocilizumab-treated patients. (C2) The changes in AI, mFRS, and IR after 6 months of therapy in tocilizumab-treated patients. (D1) The changes in serum levels of lipid profile after 6 months treatment in biologic-naïve patients. (D2) The changes in AI, mFRS, and IR after 6 months treatment in biologic-naïve patients.Back to article page